Tetraspanins in the immune response against cancer

Immunology Letters

Volumn 138, Issue 2, 2011, Pages 129-136

  Veenbergen, Sharon ^a   van Spriel, Annemiek B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Leukocyte; Microdomain; Tetraspanin; Tumor immunity

Indexed keywords

TETRASPANIN;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOLOGY; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL MEMBRANE; DENDRITIC CELL; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; ANTIGENS, CD; B-LYMPHOCYTES; CELL COMMUNICATION; CELL MEMBRANE; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INTEGRINS; KILLER CELLS, NATURAL; MICE; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RATS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TETRASPANINS;

EID: 79959546895     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.03.010     Document Type: Article

References (119)

1. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest 2007, 117:1137-1146.
2. Bindea G., Mlecnik B., Fridman W.H., Pages F., Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010, 22:215-222.
3. Birkeland S.A., Storm H.H., Lamm L.U., Barlow L., Blohme I., Forsberg B., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995, 60:183-189.
4. Gatti R.A., Good R.A. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971, 28:89-98.
5. Ma Y., Aymeric L., Locher C., Kroemer G., Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011, 23:146-152.
6. Palucka K., Ueno H., Fay J., Banchereau J. Dendritic cells and immunity against cancer. J Intern Med 2011, 269:64-73.
7. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
8. Leslie D.S., Vincent M.S., Spada F.M., Das H., Sugita M., Morita C.T., et al. CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med 2002, 196:1575-1584.
9. Shimizu K., Kurosawa Y., Taniguchi M., Steinman R.M., Fujii S. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007, 204:2641-2653.
10. Vitale M., Della C.M., Carlomagno S., Pende D., Arico M., Moretta L., et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005, 106:566-571.
11. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-355.
12. Piersma S.J., Jordanova E.S., van Poelgeest M.I., Kwappenberg K.M., van der Hulst J.M., Drijfhout J.W., et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007, 67:354-361.
13. Kohrt H.E., Nouri N., Nowels K., Johnson D., Holmes S., Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005, 2:e284.
14. Wahlin B.E., Sander B., Christensson B., Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007, 13:388-397.
15. Knutson K.L., Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54:721-728.
16. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007, 178:6730-6733.
17. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
18. Muranski P., Restifo N.P. Does IL-17 promote tumor growth?. Blood 2009, 114:231-232.
19. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010, 10:248-256.
20. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
21. Nelson B.H. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010, 185:4977-4982.
22. Coronella J.A., Spier C., Welch M., Trevor K.T., Stopeck A.T., Villar H., et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002, 169:1829-1836.
23. Reuschenbach M., von Knebel D.M., Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009, 58:1535-1544.
24. Armstrong A.C., Eaton D., Ewing J.C. Science, medicine, and the future: cellular immunotherapy for cancer. BMJ 2001, 323:1289-1293.
25. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
26. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
27. Hsu P.P., Sabatini D.M. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707.
28. Finn O.J. Cancer immunology. N Engl J Med 2008, 358:2704-2715.
29. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
30. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
31. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-779.
32. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001, 7:1339-1346.
33. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
34. Viguier M., Lemaitre F., Verola O., Cho M.S., Gorochov G., Dubertret L., et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-1453.
35. Singer S.J., Nicolson G.L. The fluid mosaic model of the structure of cell membranes. Science 1972, 175:720-731.
36. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
37. Simons K., Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39.
38. Nicolau D.V., Burrage K., Parton R.G., Hancock J.F. Identifying optimal lipid raft characteristics required to promote nanoscale protein-protein interactions on the plasma membrane. Mol Cell Biol 2006, 26:313-323.
39. Sharma P., Varma R., Sarasij R.C., Ira, Gousset K., Krishnamoorthy G., et al. Nanoscale organization of multiple GPI-anchored proteins in living cell membranes. Cell 2004, 116:577-589.
40. Jacobson K., Mouritsen O.G., Anderson R.G. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 2007, 9:7-14.
41. Parton R.G. Caveolae-from ultrastructure to molecular mechanisms. Nat Rev Mol Cell Biol 2003, 4:162-167.
42. Rubinstein E., Le Naour F., Lagaudriere-Gesbert C., Billard M., Conjeaud H., Boucheix C. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 1996, 26:2657-2665.
43. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009, 9:40-55.
44. Boucheix C., Duc G.H., Jasmin C., Rubinstein E. Tetraspanins and malignancy. Expert Rev Mol Med 2001, 2001:1-17.
45. Richardson M.M., Jennings L.K., Zhang X.A. Tetraspanins and tumor progression. Clin Exp Metastasis 2011, 28:261-270.
46. Stipp C.S., Kolesnikova T.V., Hemler M.E. Functional domains in tetraspanin proteins. Trends Biochem Sci 2003, 28:106-112.
47. Boucheix C., Rubinstein E., Tetraspanins Cell Mol Life Sci 2001, 58:1189-1205.
48. Hemler M.E. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003, 19:397-422.
49. Wright M.D., Tomlinson M.G. The ins and outs of the transmembrane 4 superfamily. Immunol Today 1994, 15:588-594.
50. Levy S., Shoham T. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 2005, 20:218-224.
51. Odintsova E., Sugiura T., Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000, 10:1009-1012.
52. Shi W., Fan H., Shum L., Derynck R. The tetraspanin CD9 associates with transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor activation and cell proliferation. J Cell Biol 2000, 148:591-602.
53. Levy S., Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 2005, 5:136-148.
54. Tarrant J.M., Robbt L., van Spriel A.B., Wright M.D. Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol 2003, 24:610-617.
55. Claas C., Stipp C.S., Hemler M.E. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001, 276:7974-7984.
56. Barreiro O., Zamai M., Yanez-Mo M., Tejera E., Lopez-Romero P., Monk P.N., et al. Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms. J Cell Biol 2008, 183:527-542.
57. Charrin S., Le Naour F., Silvie O., Milhiet P.E., Boucheix C., Rubinstein E. Lateral organization of membrane proteins: tetraspanins spin their web. Biochem J 2009, 420:133-154.
58. Espenel C., Margeat E., Dosset P., Arduise C., Le Grimellec C., Royer C.A., et al. Single-molecule analysis of CD9 dynamics and partitioning reveals multiple modes of interaction in the tetraspanin web. J Cell Biol 2008, 182:765-776.
59. Gartlan K.H., Belz G.T., Tarrant J.M., Minigo G., Katsara M., Sheng K.C., et al. A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol 2010, 185:3158-3166.
60. Knobeloch K.P., Wright M.D., Ochsenbein A.F., Liesenfeld O., Lohler J., Zinkernagel R.M., et al. Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol 2000, 20:5363-5369.
61. Maecker H.T., Levy S. Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med 1997, 185:1505-1510.
62. Miyazaki T., Muller U., Campbell K.S. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J 1997, 16:4217-4225.
63. Takeda Y., He P., Tachibana I., Zhou B., Miyado K., Kaneko H., et al. Double deficiency of tetraspanins CD9 and CD81 alters cell motility and protease production of macrophages and causes chronic obstructive pulmonary disease-like phenotype in mice. J Biol Chem 2008, 283:26089-26097.
64. Tarrant J.M., Groom J., Metcalf D., Li R., Borobokas B., Wright M.D., et al. The absence of Tssc6, a member of the tetraspanin superfamily, does not affect lymphoid development but enhances in vitro T-cell proliferative responses. Mol Cell Biol 2002, 22:5006-5018.
65. Wright M.D., Geary S.M., Fitter S., Moseley G.W., Lau L.M., Sheng K.C., et al. Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 2004, 24:5978-5988.
66. Wright M.D., Moseley G.W., van Spriel A.B. Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens 2004, 64:533-542.
67. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001, 114:4143-4151.
68. Vogt A.B., Spindeldreher S., Kropshofer H. Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains. Immunol Rev 2002, 189:136-151.
69. Engering A., Pieters J. Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells. Int Immunol 2001, 13:127-134.
70. Kropshofer H., Spindeldreher S., Rohn T.A., Platania N., Grygar C., Daniel N., et al. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat Immunol 2002, 3:61-68.
71. Unternaehrer J.J., Chow A., Pypaert M., Inaba K., Mellman I. The tetraspanin CD9 mediates lateral association of MHC class II molecules on the dendritic cell surface. Proc Natl Acad Sci USA 2007, 104:234-239.
72. Sheng K.C., van Spriel A.B., Gartlan K.H., Sofi M., Apostolopoulos V., Ashman L., et al. Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol 2009, 39:50-55.
73. Mantegazza A.R., Barrio M.M., Moutel S., Bover L., Weck M., Brossart P., et al. CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood 2004, 104:1183-1190.
74. Berditchevski F., Odintsova E. Tetraspanins as regulators of protein trafficking. Traffic 2007, 8:89-96.
75. Pols M.S., Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009, 315:1584-1592.
76. Artavanis-Tsakonas K., Kasperkovitz P.V., Papa E., Cardenas M.L., Khan N.S., Van der Veen A.G., et al. The tetraspanin CD82 is specifically recruited to fungal and bacterial phagosomes prior to acidification. Infect Immun 2011, 79:1098-1106.
77. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483.
78. Classen A., Lloberas J., Celada A. Macrophage activation: classical versus alternative. Methods Mol Biol 2009, 531:29-43.
79. Meyer-Wentrup F., Figdor C.G., Ansems M., Brossart P., Wright M.D., Adema G.J., et al. Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. J Immunol 2007, 178:154-162.
80. Suzuki M., Tachibana I., Takeda Y., He P., Minami S., Iwasaki T., et al. Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation. J Immunol 2009, 182:6485-6493.
81. Pfeiffer A., Bottcher A., Orso E., Kapinsky M., Nagy P., Bodnar A., et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol 2001, 31:3153-3164.
82. Kaji K., Takeshita S., Miyake K., Takai T., Kudo A. Functional association of CD9 with the Fc gamma receptors in macrophages. J Immunol 2001, 166:3256-3265.
83. Yauch R.L., Berditchevski F., Harler M.B., Reichner J., Hemler M.E. Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol Biol Cell 1998, 9:2751-2765.
84. Skubitz K.M., Campbell K.D., Iida J., Skubitz A.P. CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. J Immunol 1996, 157:3617-3626.
85. Midorikawa Y., Yamashita T., Sendo F. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res 1990, 50:6243-6247.
86. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006, 103:12493-12498.
87. Di C.E., Forni G., Lollini P., Colombo M.P., Modesti A., Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001, 97:339-345.
88. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194.
89. Yang Q., Goding S.R., Hokland M.E., Basse P.H. Antitumor activity of NK cells. Immunol Res 2006, 36:13-25.
90. Kramer B., Schulte D., Korner C., Zwank C., Hartmann A., Michalk M., et al. Regulation of NK cell trafficking by CD81. Eur J Immunol 2009, 39:3447-3458.
91. Tseng C.T., Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002, 195:43-49.
92. Crotta S., Ronconi V., Ulivieri C., Baldari C.T., Valiante N.M., Abrignani S., et al. Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells. Eur J Immunol 2006, 36:919-929.
93. Horvath G., Serru V., Clay D., Billard M., Boucheix C., Rubinstein E. CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82. J Biol Chem 1998, 273:30537-30543.
94. Bradbury L.E., Kansas G.S., Levy S., Evans R.L., Tedder T.F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 1992, 149:2841-2850.
95. Cherukuri A., Shoham T., Sohn H.W., Levy S., Brooks S., Carter R., et al. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. J Immunol 2004, 172:370-380.
96. Nichols T.C., Guthridge J.M., Karp D.R., Molina H., Fletcher D.R., Holers V.M. Gamma-glutamyl transpeptidase, an ecto-enzyme regulator of intracellular redox potential, is a component of TM4 signal transduction complexes. Eur J Immunol 1998, 28:4123-4129.
97. Tsitsikov E.N., Gutierrez-Ramos J.C., Geha R.S. Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci USA 1997, 94:10844-10849.
98. Shoham T., Rajapaksa R., Boucheix C., Rubinstein E., Poe J.C., Tedder T.F., et al. The tetraspanin CD81 regulates the expression of CD19 during B cell development in a postendoplasmic reticulum compartment. J Immunol 2003, 171:4062-4072.
99. Coffey G.P., Rajapaksa R., Liu R., Sharpe O., Kuo C.C., Krauss S.W., et al. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci 2009, 122:3137-3144.
100. Feigelson S.W., Grabovsky V., Shamri R., Levy S., Alon R. The CD81 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening to vascular cell adhesion molecule 1 (VCAM-1) under shear flow. J Biol Chem 2003, 278:51203-51212.
101. van Zelm M.C., Smet J., Adams B., Mascart F., Schandene L., Janssen F., et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010, 120:1265-1274.
102. van Spriel A.B., Sofi M., Gartlan K.H., van der Schaaf A., Verschueren I., Torensma R., et al. The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity. PLoS Pathog 2009, 5:e1000338.
103. Rops A.L., Figdor C.G., van der Schaaf A., Tamboer W.P., Bakker M.A., Berden J.H., et al. The tetraspanin CD37 protects against glomerular IgA deposition and renal pathology. Am J Pathol 2010, 176:2188-2197.
104. Delaguillaumie A., Lagaudriere-Gesbert C., Popoff M.R., Conjeaud H. Rho GTPases link cytoskeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes. J Cell Sci 2002, 115:433-443.
105. Mittelbrunn M., Yanez-Mo M., Sancho D., Ursa A., Sanchez-Madrid F. Cutting edge: dynamic redistribution of tetraspanin CD81 at the central zone of the immune synapse in both T lymphocytes and APC. J Immunol 2002, 169:6691-6695.
106. Lebel-Binay S., Lagaudriere C., Fradelizi D., Conjeaud H. CD82, member of the tetra-span-transmembrane protein family, is a costimulatory protein for T cell activation. J Immunol 1995, 155:101-110.
107. Tai X.G., Yashiro Y., Abe R., Toyooka K., Wood C.R., Morris J., et al. A role for CD9 molecules in T cell activation. J Exp Med 1996, 184:753-758.
108. Lagaudriere-Gesbert C., Le Naour F., Lebel-Binay S., Billard M., Lemichez E., Boquet P., et al. Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF activity. Cell Immunol 1997, 182:105-112.
109. van Spriel A.B., Puls K.L., Sofi M., Pouniotis D., Hochrein H., Orinska Z., et al. A regulatory role for CD37 in T cell proliferation. J Immunol 2004, 172:2953-2961.
110. Imai T., Kakizaki M., Nishimura M., Yoshie O. Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82. J Immunol 1995, 155:1229-1239.
111. Maecker H.T., Do M.S., Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc Natl Acad Sci USA 1998, 95:2458-2462.
112. Deng J., Yeung V.P., Tsitoura D., DeKruyff R.H., Umetsu D.T., Levy S. Allergen-induced airway hyperreactivity is diminished in CD81-deficient mice. J Immunol 2000, 165:5054-5061.
113. Maecker H.T. Human CD81 directly enhances Th1 and Th2 cell activation, but preferentially induces proliferation of Th2 cells upon long-term stimulation. BMC Immunol 2003, 4:1.
114. Deng J., DeKruyff R.H., Freeman G.J., Umetsu D.T., Levy S. Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses. Int Immunol 2002, 14:513-523.
115. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
116. van Spriel A.B. Tetraspanins in the humoral immune response. Biochem Soc Trans 2011, 39:512-517.
117. O'Neill D.W. Dendritic cells and T cells in immunotherapy. J Drugs Dermatol 2010, 9:1383-1392.
118. Figdor C.G., de Vries I.J., Lesterhuis W.J., Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10:475-480.
119. Lesterhuis W.J., de Vries I.J., Adema G.J., Punt C.J. Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Ann Oncol 2004, 15(Suppl. 4):iv145-iv151.